Adamis Pharmaceuticals Corporation
0.00 (0.0%)


Draw Mode:

Volume 0
Bid Price 0.1139
Ask Price 0.1198
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Adamis Pharmaceuticals Corporation ADMP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.119 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.0992 - 0.62
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.119 USD

Adamis Pharmaceuticals Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 19.81M 166.48M 165.91M $ 4.85M $ - -0.19 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 5.70%

more financials information »

Adamis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ADMP Message Board. Create One! See More Posts on ADMP Message Board See More Message Board Posts

Historical ADMP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.10470.130.09920.11232841,041,9290.014313.66%
1 Month0.290.310.09920.176312,778,502-0.171-58.97%
3 Months0.16480.310.09920.18891811,378,804-0.0458-27.79%
6 Months0.26190.310.09920.17345561,540,343-0.1429-54.56%
1 Year0.620.620.09920.24809441,122,254-0.501-80.81%
3 Years0.402.340.09921.014,629,473-0.281-70.25%
5 Years3.455.100.09921.103,083,946-3.33-96.55%

Adamis Pharmaceuticals Description

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.